Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment

Recruiting

Phase 1

Phase 2

Tazemetostat, Dabrafenib, TrametinibTesting the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment

Sponsor:

National Cancer Institute (NCI)

Code:

NCT04557956

Conditions

Clinical Stage IV Cutaneous Melanoma AJCC v8

Metastatic Melanoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biopsy Procedure

Computed Tomography

Dabrafenib Mesylate

Echocardiography Test

Magnetic Resonance Imaging

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-14. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2025-09-03.